SCHEMBL3832793

SCHEMBL3832793

CN1CCC(c2ccc(Cl)cc2)C(CO)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7812339 1.00 SLC6A3 (0.72) SLC6A3
SCHEMBL3833872 1.00 SLC6A3 (0.72) SLC6A3
SCHEMBL1086583 1.00 SLC6A3 (0.72) SLC6A3
SCHEMBL3832789 1.00 SLC6A3 (0.72) SLC6A3
SCHEMBL7812342 1.00 SLC6A3 (0.72) SLC6A3
SCHEMBL3833873 1.00 SLC6A3 (0.72) SLC6A3
SCHEMBL6826523 0.86 SLC6A3 (0.54) SLC6A3
SCHEMBL7684279 0.86 SLC6A3 (0.73) SLC6A3
SCHEMBL3921318 0.85 SLC6A3 (0.52) SLC6A3
SCHEMBL7679057 0.85 SLC6A3 (0.52) SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0975595-B9 ANALOGS OF COCAINE UNIV GEORGETOWN (US) 2009-09-16 EP disclosed
EP-0975595-B1 ANALOGS OF COCAINE UNIV GEORGETOWN (US) 2009-06-17 EP disclosed
US-6806281-B2 TREATMENT OF COCAINE ABUSE, PARKINSON'S DISEASE GEORGETOWN UNIVERSITY 2004-10-19 US disclosed
US-6605621-B1 Safe and effective detoxification after treating drug addiction, or diseases wherein cocaine is administered GEORGETOWN UNIVERSITY 2003-08-12 US disclosed
US-20030144322-A1 Analogs of cocaine NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-07-31 US disclosed
US-20030144289-A1 Monomeric and dimeric heterocycles, and therapeutic uses thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-07-31 US disclosed
US-6472422-B2 TREATING DRUG ADDICTION GEORGETOWN UNIVERSITY 2002-10-29 US disclosed
US-6440996-B1 Monomeric and dimeric heterocycles, and therapeutic uses thereof GEORGETOWN UNIVERSITY 2002-08-27 US disclosed
US-20020055521-A1 Analogs of cocaine NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-05-09 US disclosed
EP-1119553-A1 MONOMERIC AND DIMERIC HETEROCYCLES, AND THERAPEUTIC USES THEREOF GEORGETOWN UNIVERSITY (US) 2001-08-01 EP disclosed
US-6180648-B1 Analogs of cocaine BIOSTREAM THERAPEUTICS, INC. 2001-01-30 US disclosed
WO-2000020390-A1 MONOMERIC AND DIMERIC HETEROCYCLES, AND THERAPEUTIC USES THEREOF GEORGETOWN UNIVERSITY (US) 2000-04-13 WO disclosed
EP-0975595-A1 ANALOGS OF COCAINE GEORGETOWN UNIVERSITY (US) 2000-02-02 EP disclosed
WO-1998045263-A1 ANALOGS OF COCAINE GEORGETOWN UNIVERSITY (US) 1998-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055521-A1 Analogs of cocaine CES2, OPRM1, OPRD1 SLC6A3 20/4885
US-20030144289-A1 Monomeric and dimeric heterocycles, and therapeutic uses thereof HAX1, MLX, XDH SLC6A3 85/4885
US-20030144322-A1 Analogs of cocaine CES2, OPRM1, OPRD1 SLC6A3 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.